Welcome visitor Log In - or - Register
0 items /
View Cart
Check Out
four ways
Quick Search:
Skip Navigation LinksHome > Kinase Inhibitors > Bcr-Abl/c-kit/PDGFR/Src > DCC-2036 (Rebastinib)
DCC-2036 (Rebastinib)
DCC-2036 is a unique switch-pocket, non-ATP competitive (allosteric) inhibitor with IC50 at low nanomolar concentration against a number of tyrosine kinases including FLT3 (1.7 nM), TRKA (7.0 nM), TIE-2 (2.7 nM) and BCR-ABL (2.0 nM). DCC-2036 has shown promising activity in a phase I/II clinical trial in chronic myeloid leukemia (CML), where plasma concentrations of 350 nM of DCC-2036 have been safely achieved. DCC-2036 has induced clinical and molecular remissions in patients with TKI-resistant CML expressing the ‘gate-keeper’ T315I BCR-ABL mutation, as well as demonstrated activity against mutations that cause BCR-ABL conformational escape resistant.
Catalog NO: CT-DCC20
Synonym: Rebastinib
CAS NO: 1020172-07-9
Mol. Formula: C30H28FN7O3
MW: 553.59
** Please ask for quote for other quantities. In stock, prompt..